SCHEMBL2804187

SCHEMBL2804187

O=S(=O)(NC1CCc2c(cnc3[nH]ncc23)C1)c1ccc(Cl)c(C(F)(F)F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.44
MAPK1 P28482 2/20 0.41
HDAC8 Q9BY41 2/20 0.39
TSHR P16473 1/20 0.39
LMNA P02545 2/20 0.38
ALDH1A1 P00352 1/20 0.38
CCR2 P41597 2/20 0.38
RAF1 P04049 1/20 0.36
PDGFRB P09619 1/20 0.36
KIT P10721 1/20 0.36
PDGFRA P16234 1/20 0.36
FGFR2 P21802 1/20 0.36
KDR P35968 1/20 0.36
FLT3 P36888 1/20 0.36
MEP1B Q16820 1/20 0.36
PLAU P00749 1/20 0.36
CYP2C9 P11712 1/20 0.36
JAK1 P23458 1/20 0.36
TBXA2R P21731 1/20 0.35
PNMT P11086 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2808103 0.89 HDAC8 (0.49) MAPK1HDAC8LMNAALDH1A1PLAU
SCHEMBL2806129 0.85 KCNH2 (0.41) HDAC8TBXA2R
SCHEMBL2804144 0.84 TBXA2R (0.42) HDAC8LMNAALDH1A1KITPLAU
SCHEMBL2804161 0.84 ALDH1A1 (0.39) HDAC8TSHRLMNAALDH1A1JAK1
SCHEMBL2804200 0.84 HDAC8 (0.52) CYP3A4HDAC8TSHRLMNACYP2C9
SCHEMBL2807111 0.83 KMT2A (0.50) HDAC8TSHRLMNAALDH1A1TBXA2R
SCHEMBL2804752 0.82 HDAC8 (0.50) HDAC8KITTBXA2RTBXAS1
SCHEMBL2802939 0.82 HDAC8 (0.39) CYP3A4HDAC8FLT3
SCHEMBL2803941 0.82 ALDH1A1 (0.49) HDAC8LMNAALDH1A1TBXA2RPNMT
SCHEMBL2805699 0.82 RB1 (0.52) HDAC8KITCYP2C9JAK1TBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 CYP3A4 811/4885MAPK1 3253/4885HDAC8 615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.